Page last updated: 2024-11-06

n'-methyl-2-pyridone-5-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N'-methyl-2-pyridone-5-carboxamide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-methyl-6-pyridone-3-carboxamide : A pyridone that is 2-pyridone substituted with a carboxamide group at C-5 and a methyl group at N-1. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID69698
CHEMBL ID3542314
CHEBI ID27410
SCHEMBL ID709323
MeSH IDM0046586

Synonyms (44)

Synonym
2py ,
1-methyl-5-carboxylamide-2-pyridone
n1-methyl-2-pyridone-5-carboxamide
C05842 ,
n'-methyl-2-pyridone-5-carboxamide
701-44-0
1-methyl-6-oxopyridine-3-carboxamide
1-methyl-6-oxo-1,6-dihydropyridine-3-carboxamide
1,6-dihydro-1-methyl-6-oxonicotinamide
nudifloramide
n-methyl-2-pyridoxone-5-carboxamide
3-carbamoyl-1-methyl-6-pyridone
AKOS003297743
68139usc7w ,
3-pyridinecarboxamide, 1,6-dihydro-1-methyl-6-oxo-
unii-68139usc7w
n-methyl-6-pyridone-3-carboxamide
CHEBI:27410 ,
n(1)-methyl-2-pyridone-5-carboxamide
n-methyl-2-pyridone-5-carboxamide
FT-0673170
FT-0673169
SCHEMBL709323
DTXSID70220374
nicotinamide, 1,6-dihydro-1-methyl-6-oxo-
1-methyl-6-oxo-1,6-dihydro-3-pyridinecarboxamide #
JLQSXXWTCJPCBC-UHFFFAOYSA-N
1-methyl-6-pyridone-3-carboxylamide
n1-methyl-2-pyridone-5-carboxyamide
1-methyl-6-oxo-pyridine-3-carboxamide
CHEMBL3542314 ,
mfcd00457283
n'methyl-2-pyridone-5-carboxamide
HY-113432
CS-0059507
DS-8079
Q27103116
nudifloramide; lc-tdda; ce10
C76234
A866667
bdbm50455093
1,6-dihydro-1-methyl-6 -oxonicotinamide
EN300-174679
SB76509

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The method was sensitive, specific, precise, accurate and suitable for bioequivalence and pharmacokinetic studies."( Simultaneous determination of niacin and its metabolites--nicotinamide, nicotinuric acid and N-methyl-2-pyridone-5-carboxamide--in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Damaramadugu, R; Inamadugu, JK; Mullangi, R; Ponneri, V, 2010
)
0.36

Bioavailability

ExcerptReferenceRelevance
" Since both drugs are extensively metabolized, this study investigated the bioavailability and pharmacokinetics of their co-administration following single-dose administration."( The comparative bioavailability of an extended-release niacin and lovastatin fixed dose combination tablet versus extended-release niacin tablet, lovastatin tablet and a combination of extended-release niacin tablet and lovastatin tablet.
Cefali, E; Menon, R; Tolbert, D, 2007
)
0.34

Dosage Studied

ExcerptRelevanceReference
" Twelve healthy males were enrolled in an open-label, dose-rate escalation study and received 2000 mg niacin at 3 different dosing rates."( Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites.
Adams, MH; Cefali, EA; González, MA; Leu, JH; Menon, RM; Tolbert, DS, 2007
)
0.34
" In particular, because of the endogenous NAM and 2-Pyr in human plasma, the concentrations of NAM and 2-Pyr in human plasma after dosing were determined by subtracting blank values of them."( Simultaneous quantification of niacin and its three main metabolites in human plasma by LC-MS/MS.
Han, J; Liu, H; Liu, M; Wang, X; Xiao, X; Yang, M; Zhang, D; Zhang, L; Zhang, Y, 2012
)
0.38
" We have identified a novel nicotinamide (NA) analog, compound 12 that inhibited NNMT enzymatic activity and reduced the formation of 1-methyl-nicotinamide (MNA), the primary metabolite of NA by ∼80% at 2 h when dosed in mice orally at 50 mg/kg."( Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase.
Anchan, NK; Bhamidipati, RK; Burri, RR; Chandrasekar, DV; Czech, J; Dhakshinamoorthy, S; Gosu, R; Hallur, MS; Kadnur, SV; Kannt, A; Kristam, R; Langer, T; Mane, VS; Marker, A; Mullangi, R; Murugesan, KR; Narasimhulu, LK; Putta, VPRK; Rajagopal, S; Rudolph, C; Ruf, S; Sarkar, S; Schreuder, H; Shaik, S; Singh, M; Suresh, J; Swamy, IN; Yura, T, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
pyridinecarboxamideA member of the class of pyridines that is a substituted pyridine in which at least one of the substituents is a carboxamide or N-substituted caraboxamide group.
pyridone
methylpyridinesAny member of the class of pyridines that carries at least one methyl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Nicotinate and Nicotinamide Metabolism1434

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nicotinamide N-methyltransferaseHomo sapiens (human)IC50 (µMol)30.00003.62004.41005.2000AID1374430
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
nicotinamide metabolic processNicotinamide N-methyltransferaseHomo sapiens (human)
response to xenobiotic stimulusNicotinamide N-methyltransferaseHomo sapiens (human)
response to organonitrogen compoundNicotinamide N-methyltransferaseHomo sapiens (human)
animal organ regenerationNicotinamide N-methyltransferaseHomo sapiens (human)
methylationNicotinamide N-methyltransferaseHomo sapiens (human)
NAD biosynthesis via nicotinamide riboside salvage pathwayNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of gluconeogenesisNicotinamide N-methyltransferaseHomo sapiens (human)
positive regulation of protein deacetylationNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
nicotinamide N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
pyridine N-methyltransferase activityNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
cytosolNicotinamide N-methyltransferaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1374430Inhibition of human NNMT at 30 uM preincubated for 30 mins followed by nicotinamide substrate and SAM addition measured after 60 mins by fluorescence assay2018Bioorganic & medicinal chemistry letters, 03-01, Volume: 28, Issue:5
Novel nicotinamide analog as inhibitor of nicotinamide N-methyltransferase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199013 (24.07)18.7374
1990's7 (12.96)18.2507
2000's15 (27.78)29.6817
2010's15 (27.78)24.3611
2020's4 (7.41)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.07 (24.57)
Research Supply Index4.14 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials8 (14.81%)5.53%
Reviews4 (7.41%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (77.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]